Researchers led by Stanford computer scientist James Zou built a system called Virtual Biotech, using up to 37,000 AI agents modeled like departments of a biotech company, overseen by a 'chief scientific officer' agent. After analyzing thousands of past clinical trials, the AI swarm flagged an immune-dampening protein as a target and, with human guidance, proposed a candidate treatment for lung cancer, detailed in a new Science paper.
nature.com
· 2026-09-17
A retired NYPD officer treated for lung cancer linked to ground zero exposure describes losing multiple friends—construction workers, firefighters and police—to cancers and respiratory illness in the years after 9/11. The 25th anniversary ceremony at the World Trade Center will include a new moment of silence honoring those who died from post-exposure illnesses rather than the attacks themselves.
statnews.com
· 2026-09-11
Researchers report findings on biological markers that correlate with improved patient outcomes when immune-based therapies are used before and after surgery for lung cancer. The publication, appearing on Nature's platform, outlines how certain biomarkers may help predict which patients respond best to this perioperative treatment approach.
nature.com
· 2026-09-02
A week after its US approval for advanced pancreatic cancer, the drug daraxonrasib has shown early promise against non-small cell lung cancer, the most common form of the disease. In a small trial published in the New England Journal of Medicine, tumors shrank in over 30% of patients whose cancers carried mutations in RAS family proteins and who had already failed other treatments. A larger randomized trial comparing daraxonrasib to standard chemotherapy is now underway.
nature.com
· 2026-09-02
GoKawiil